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Historical Background 
Prostate cancer encompasses a heterogeneous 
assembly of tumors, with distinctive risk factors, 
clinical presentation, histopathological features and 
molecular uniqueness. Currently, cure of metastatic 
or recurrent disease is dependent on conventional 
chemotherapy combination regimens. It is a matter 
of deep concern that efficient clinical management 
of prostate cancer has been relentlessly challenged 
by considerable intratumoral multiplicity at genomic 
and pathological levels and a limited understanding 
of the genetic elements governing disease 
development. Prostate cancer (PCa) cells remarkably 
express androgen receptor (AR) and need androgens 
to survive. Androgen suppression is doubtlessly, 
front-line therapy for metastatic disease. Almost all 
PCa patients at the start show responsiveness to 
hormonal therapy but gradually show refractoriness 
to castration. There is an accumulating confirmation 
that these tumors are relying on AR signaling. 
Numerous mechanisms that augment AR signaling 
in an androgen-depleted environment have been 
explicated. Normal development of prostate gland is 
directly related to normal functioning of androgen 
receptor (AR) as its critically important in prostate 
carcinogenesis and androgen-dependent (AD) or 
androgen independent (AI) progression of the 
disease. Functional AR is expressed during various 
stages of prostate carcinogenesis from the very early 
stage of prostate intraepithelial neoplasia to organ-
confined or locally invasive primary tumors, in 
metastatic tumor and before or after androgen-
deprivation therapy (ADT) (1-3). When activated by 
the endogenous androgenic ligands, testosterone (T) 
Androgen receptor (AR) is a nuclear transcription factor and a 
member of the steroid hormone receptor superfamily of genes, which 
is abundantly expressed in neuroendocrine and musculoskeletal 
tissues and the male genitourinary system. Neoplastic cells have to 
perpetuate the androgen receptor (AR)-mediated dynamics by a wide 
range of integrated pathways that crosstalk at various levels and it 
ensures the robust expression and activation of AR-mediated genes. 
There are multidirectional pathways opted for by the AR to meet the 
demands of a desperate cancer-prone environment. Interference with 
these histone demethylases with siRNA or pharmacological 
inhibitors leads to distinct changes in histone marks at AR target 
promoters. Several inhibitors such as CaMKII inhibitor have been 
found to have a broader effect on apoptosis than just their inhibition 
which also resulted in the inhibition of AR activity and induces p53-
independent apoptosis, inhibits anti-apoptotic protein Mcl-1, 
upregulates pro-apoptotic protein PUMA and generates ROS. 
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and dihydrotestosterone (DHT), AR becomes 
phosphorylated and the ligand-receptor complex 
translocates into the nucleus, and in association with 
coregulatory factors, binds to specific genomic DNA 
(gDNA) sequences in the regulatory regions of AR 
target genes. 
Prostate carcinogenesis and the molecular events 
involved in it are essentially to be known before 
developing any therapeutic strategies to prevent AR-
dependent signaling and progression of PCa. It also 
has been observed that AR target genes such as PSA 
expression remains high in spite of AR blockage in 
hormone-refractory PCa (HRPCa) patients (4). Lack 
of precise information regarding the molecular 
mechanisms of AI-PCa development is the 
challenging task while developing a therapeutic 
strategy, but while studying the literature we came to 
know that physical presence and activity of AR are 
critical factors. In a relatively large number of AI-
PCa patients, AR is expressed, over expressed, 
mutated or amplified (5, 6). It also has been 
observed that cytokines, polypeptide growth factors, 
neuropeptides, non-androgenic steroid hormones, 
antiandrogens and other trophic agents activate the 
AR-dependent and AI-signaling pathways (7). These 
non-androgenic factors can regulate AR expression 
and/or activity through establishment of downstream 
cytoplasmic signaling crosstalk or cross-modulation 
by other transcription factors (8). The net effect of 
these events could potentially contribute to AI 
progression of PCa. It also has been believed that 
genomic mutations and amplifications could be the 
major cause of aberrant AR activation in AI-PCa. 
Collectively, advanced PCa will acquire the 
phenotype of oncogenic addiction to AR and 
continue to grow and resist available therapeutic 
regimens. More than 60 years ago, Huggins and 
Hodges (9) showed the effectiveness of surgical 
castration in men with prostate cancer (PCa). Since 
that time, hormonal therapy remains as the most 
effective and widely used palliative method for 
advanced and/or metastatic PCa. This method leads 
to a biochemical response in the majority of patients 
for up to 3 years, but eventually and almost 
exclusively during therapy, an incurable highly 
aggressive AI- or hormone-refractory disease will 
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will emerge (10). Current comprehensive 
introduction and critical review of literature will 
give a snapshot of AR involvement in prostatic 
carcinogenesis.  
 
AR Structure and Signaling 
AR Structure 
The AR is a nuclear transcription factor and a 
member of the steroid hormone receptor superfamily 
of genes, which includes but is not limited to the 
receptors for estrogen, progesterone, 
glucocorticoids, mineralocorticoids, vitamin D, 
retinoic acid and retinoid X. With the exception of 
the spleen, the AR is abundantly expressed in 
neuroendocrine and musculoskeletal tissues and the 
male genitourinary system (11). The AR gene is 
located on the X-chromosome at position Xq11-12 
and spans ~90 kb containing eight exons that code 
for a ~2757 bp open reading frame and ~919 amino 
acids within a 10.6 kb mRNA. AR expression is 
expressed in two isoforms: the predominant isoform 
B with 110 kDa mass and the less dominant isoform 
A with ~80 kDa. In addition to these two isoforms, a 
recent report described additional novel AR splice 
variants designated as AR3, AR4 and AR5 in 
androgen-insensitive PCa cell lines (see reference 
(12) for detailed description). A highly conserved 
AR genomic has been observed throughout 
evolutionary lineage of mammals. 
Similar to many other steroid receptors, the AR 
consists of distinct functional motifs organized as 
the amino-terminal domain (NTD; 555 amino acids 
coded by exon 1), DNA binding domain (DBD; 68-
amino acid coded by exon 2 and 3), ligand-binding 
domain (LBD; 295 amino acids coded by exons 4–
8), nuclear localization (amino acid 628–657) and 
AF-1, AF-5 and AF-2 transactivation units encoded 
by exon 1 and 8. A hinge region separates LBD from 
DBD. On the contrary to the very high evolutionary 
conservation for LBD, DBD and the N-terminal of 
the hinge fragment, the most variable region is the 
NTD sequence. This domain is encoded by several 
regions of highly repetitive DNA sequences, such as 
CAG and GGC repeats. Similar to other nuclear 
receptors, the DBD region of AR contains nine 
cysteines, of which eight are linked to two zinc ions, 
and through the sulfohydryl groups they are 
organized in two zinc finger domains. The AR–DNA 
recognition specificity is determined by the first zinc 
finger and stabilization of the DNA–receptor 
complex, and receptor dimerization is determined by 
the second zinc finger.  
 
AR coregulators 
After the discovery of first steroid receptor 
coactivator (SRC-1), over 170 potential AR 
coregulators have been identified (13). This growing 
list of coregulators has been functionally classified 
as coactivators or corepressors, or, on the basis of 
their best recognized primary function, as 
components of the chromatin remodeling complex, 
as histone modifiers such as acetyl-transferases and 
deacetylases, methyltransferases or demethylases, as 
components of the ubiquitination and proteasomal 
pathways, as components of the sumoylation 
pathway, as proteins involved in endocytosis, DNA 
repair system, splicing and RNA metabolism, or as 
chaperones and cochaperones, cytoskeletal proteins,  
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signal integrators, transducers, scaffolds and 
adaptors, or cell cycle or apoptosis regulators (14). 
On activation by ligand and nuclear translocation, 
AR binds to the androgen-response elements (AREs) 
that may also involve or recruit coregulators to 
assemble a functional transcriptional complex 
regulating AR target gene transcription. 
In addition, AR coregulators may at least partially 
contribute to differences in AR ligand specificity or 
its transcriptional activity (15). It has been shown 
that the expression of SRC-1, TIF-2 and SRC-3, the 
three members of the SRC or p160 family of 
coactivators, is increased in PCa (16). SRC-1 
expression is increased in 50% of AD-PCa samples, 
as compared with the benign or normal prostate 
tissues. However, SRC-1 and TIF-2 expression are 
increased in 63% of HRPCa (17). In another study, 
an increased expression of SRC-3 was associated 
with increased PCa grade and stage and decreased 
disease-free survival. The AR coactivator ARA70 is 
also overexpressed in PCa samples (18) and after 
castration in the hormone-refractory CWR22 
xenografts. The Cdc25B (cdk-activating 
phosphatase) was also identified as an AR 
coactivator, and found not only to be overexpressed 
in PCa but also with the highest expression in 
advanced-stage tumors with high Gleason score 
(19). The AR coactivator, Tat interactive protein, 60 
kDa (Tip60), was found to be overexpressed on 
androgen deprivation in the LNCaP cells and 
CWR22 tumor xenograft (20). Overall, these studies 
support that PCa is associated with overexpression 
of multiple AR coactivators and may contribute to 
PCa progression. Taking into consideration of the 
simultaneous involvement of multiple coregulators 
and their overlapping interaction, additional 
translational studies are required to determine the 
contribution of AR coregulators in prostate 
carcinogenesis and PCa progression in experimental 
settings. 
 
Coactivators 
To date, several hundred putative AR coactivators 
have been identified that enhance ligand dependent 
AR activity in model systems. These coactivators 
serve pleiotropic functions at the chromatin level, 
including recruitment of basal transcriptional 
machinery, modulation of chromatin remodeling 
Vol. 3, No. 2, jun, 2017 
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changes. A subset of AR coactivators appears to be 
enhanced in human disease, including SRC1, SRC2, 
SRC3, or ARA70 (21-23). The importance of 
deregulated coactivator expression may be 
significant, as excessive coactivator expression may 
not only sensitize cells to a low hormone 
environment but also convert nuclear receptor 
antagonists into partial or full agonists. As AR is 
known to regulate a distinct transcriptional program 
in hormone sensitive versus castrate-resistant models 
of disease (24), an attractive hypothesis is that 
altered cofactor expression and/or regulation assists 
in eliciting the CRPC-specific transcriptional 
program. 
Corepressors 
Loss of AR corepressor function can convert 
therapeutic antagonists into agonists or promote 
agonist sensitization (reviewed in (25)). Such events 
can occur through downregulation of the corepressor 
itself (such as occurs with prohibitin) (26), through 
dismissal of the corepressors from the AR complex 
(as seen with NCoR in the presence of macrophage 
induced TAB2 signaling), and/or through aberrant 
corepressor mislocalization (such as observed with 
Hey1) (27). In addition to AR modulation, 
corepressors perturbed in prostate cancer may 
crosstalk with pathways directly associated with 
prostate cancer growth. For example, reduction of 
the AR corepressor Ebp1 is not only associated with 
resistance to hormone therapy, but also alters the 
proliferative response to heregulin (28). Similarly, 
crosstalk between the AR and cell cycle machinery 
is mediated by cyclin D1, which acts through cyclin-
dependent kinase-independent functions to suppress 
AR activity; this function of cyclin D1 is abrogated 
in human disease through downregulation, 
mislocalization, or alternative splicing events (29, 
30).  
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enzymes function or recruitment (e.g. histone 
acetylase), and/or altered AR conformationalAs a 
result of such growth factor and cell cycle crosstalk 
functions embedded within selected AR cofactors, 
alterations therein may impinge both on AR 
signaling and connected pathways to yield a 
powerful pro-tumorigenic signal. Challenges remain 
with regard to discerning which of the several 
hundred co-repressors identified to date play critical 
roles in recurrent AR activity, and prioritizing those 
which could be developed as viable therapeutic 
targets. 
 
AR cofactors 
AR cofactors are cis-acting transcriptional 
modulatory proteins that substantially influence AR 
function. Given the prevailing posit that agonists 
induce recruitment of coactivators and antagonists 
promote conformational changes that promote 
recruitment of corepressors, two hypotheses emerge. 
First, it would be predicted that deregulation of 
coactivators or loss of corepressors promote 
unchecked AR activity and disease progression. 
Second, it is predicted that changes in overall AR 
levels alter the stoichiometry of assembled 
complexes. Both predictions appear to be correct and 
have disease relevance. 
 
AR Signaling 
Post translational modifications of AR 
Steroid receptors can be modified by a variety of 
posttranslational modifications such as 
phosphorylation, acetylation, ubiquitinylation and 
sumoylation. These changes have the potential to 
affect the receptor stability, subcellular localization, 
interaction with other proteins within the 
transcription machinery complex or activity in a cell 
type- or genespecific manner. Interestingly, the net 
effect of AR activity could be affected by crosstalk 
among different types of posttranslational 
modifications such as acetylaton and 
phosphorylation (31). It is noteworthy that the 
consequences of posttranslational modifications of 
AR in prostate carcinogenesis and progression 
remain to be understood. 
 
AR phosphorylation and dephosphorylation 
AR is a nuclear phosphoprotein/transcription factor 
and in order to exert its transcriptional role after 
synthesis, it should translocate to the nucleus and 
remain at a hyperphosphorylated level (11). 
Constitutive AR phosphorylation at serine 94 and 
ligand-induced phosphorylation are reported for 
serines 16, 81, 256, 309, 424 and 650 (32). In 
addition, mitogen-activated protein kinases (MAPK) 
and phosphatidyl inositol-3 kinase/Akt (PI3K/ Akt), 
as the two very important core-signal transduction 
pathways, are also able to induce AR 
phosphorylation. On the contrary, AR 
dephosphorylation will be associated with loss of 
AR transcriptional activity and inability for nuclear 
translocation. Protein phosphatase 2A can 
dephosphorylate AR at NTD, which leads to loss of 
AR activity (33). 
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AR acetylation 
Protein acetylation has a central regulatory role in 
transcriptional activity of genes. Activity of 
transcription factors can be also regulated by 
acetylation. For AR, the KXKK motif of the hinge 
region is the site of acetylation. Lysine to alanine 
mutation of the KXKK motif significantly reduces 
AR activity by dysregulation of stimulation of 
coactivators in favor of the N-CoR corepressors 
(34). In addition, mutations that mimic acetylation 
increase AR-target gene expression and PCa cell 
proliferation. A clear example of the crosstalk 
between acetylation and phosphorylation is provided 
by the facts that AR acetylation mutants present with 
decreased phosphorylation and the finding that AR 
(S94A) phosphorylation mutant is less responsive to 
p300 stimulation. Another report showed that 
histone deacetylase inhibitors increase AR activity 
level without affecting its sub-cellular localization 
(35). 
AR ubiquitylation 
AR turnover is not fully understood. Timely 
degradation of transcription factors is necessary as a 
control step to sustain transcriptional activity or 
eliminate it by rapidly degrading the protein. Similar 
to many other proteins, steroid receptors are also 
subjected to ubiquitylation. It has been shown that 
the E3 ubiquitin ligase Mdm2, which promotes 
polyubiquitylation of AR and its proteasomal 
degradation, recognizes Akt-dependent 
phosphorylated serine. In addition, it has been 
shown that by recruiting the histone deacetylase, 
Mdm2/AR complex decreases AR-dependent 
transcriptional activity (36). On the contrary, it was 
shown that inhibition of ubiquitylation process and 
proteasomal degradation of AR by a protease, 
USP10, functions as an AR coactivator (37). 
 
AR sumoylation 
This type of posttranslational modification usually 
affects a small portion of a given protein and leads to 
covalent binding of a small ubiquitin-like modifier 
chain on lysine residues embedded in the consensus 
ΨKxE motif. Sumoylation can affect at different 
levels such as subcellular localization and DNA 
binding. There is also a possibility for crosstalk 
between sumoylation and MAP kinase 
phosphorylation of AR (38). Sumoylation of AR is 
hormone dependent and its effect is mainly 
repressive, but still context dependent. Unlike 
ubiquitination, sumoylation does not promote 
protein degradation. In some instances, sumoylation 
competes with ubquitylation on the lysine residues 
and functions as an ubiquitin (39).  
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ARs are sumoylated at lysine 386 and 520 in vivo 
and mutation of these residues increases AR 
transactivation, that suggests a role for sumoylation 
in suppressing AR activity (40).   
 
Androgen Receptor Infrastructure: Marching to 
a different drummer  
The biological multiplicity of prostate cancer is the 
major stumbling block in the standardization of 
therapy. Currently a paradigm shift has occurred in 
the clinical management of prostate cancer. Instead 
of long term androgen ablation/deprivation therapy 
(ADT), scientists have strengthened the concept of 
intermittent ADT (Fig. 2). Progress in molecular 
profiling suggests that divergence in the genetic 
profile of tumors considerably participate to the 
intricacy of the disease. Alternative pre-mRNA 
splicing is principal genetic process involved in 
biological diversity. During alternative splicing, 
coding and noncoding regions of a single gene 
undergo rearrangement to generate several 
messenger RNA transcripts yielding discrete protein 
isoforms with multifarious biological functions. 
Dysregulation of the splicing machinery influence 
splicing of cancer-relevant genes. It is interesting to 
note that androgen receptor undertakes aberrant and 
alternative splicing and gives rise to proteins that 
influence cell phenotypes and survival of patients. 
Splicing mechanisms must be manipulated at clinical 
level. In view of the fact that splicing is concerned 
with information transfer from the genome to the 
proteome, it incorporates another vital dimension to 
'-omics'-based molecular signatures utilized to 
individualize clinical management of patients. 
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Figure 1: An overview of the transition from localized to metastatic stage. Short term (Androgen Deprivation Therapy) ADT seems to be 
more effective than long term ADT with hazardous outcomes. An intermittent ADT is more reasonable in terms of clinical management. 
Muhammad Ali Naseer and  Sara Ali  2017. The Cancer Press, 3(2): 50-66                                                                                         57 
www.thecancerpress.com 
www.imaqpress.com  
Variant are able to register full-length version of AR 
with duplicated exon 3 and two truncated versions 
lacking the COOH terminal domain (CTD). AR 
isoforms also exist in CTD-truncated version and are 
encoded by mRNAs that have a novel exon 2b at 
their 3' end. In a ligand-independent manner, AR  
isoforms promote the expression of endogenous AR-
dependent genes, as well as the proliferation of 
22Rv1 cells. However discordant finding was given 
by Marcias et al. (41), who documented a variant. 
22Rv1 cells also express a mutant AR lacking exon 
3 tandem duplication, doubtlessly, a major feature of 
this cell line. 
Shi et al. (42), registered ligand-binding domain 
deficient AR splice variants in hormone-insensitive 
PCA cells. AR3, one of the major splice variants 
expressed in human prostate tissues, is constitutively 
active and transcriptome was not triggered by 
androgens. At present available anti androgen drugs 
are unable to drug novel AR splice variants are not 
inhibited by. A rational drug design targeting these 
AR isoforms may potentially be successful for 
treatment of ablation-resistant PCA. Another novel 
human AR splice variant deficient in exons 5, 6, and 
7 (ARv567es). This accumulating data marks these 
variants as candidates for therapies directly targeting 
the AR rather than ligand. CRPC cells express 
variant ARs which included truncated ARs (tARs), 
siRNA-mediated knockdown efficiently suppressed 
the androgen-independent cell growth. Nigericin-
like compounds suppress AR expression at the 
mRNA level. This could be an approach for the 
clinical management of prostate cancer (43). It is a 
matter of deep concern for the cell to prolong the 
signaling of the cancer driving genes via AR. It 
ensures the robust expression and activation of 
androgen receptor mediated genes somehow or 
other. There are multidirectional pathways opted by 
the androgen receptor to meet the demands of 
desperate cancer prone environment. In the 
hypersensitive pathway, there is a robust quantitative 
expression of androgen receptor (AR) usually by 
gene amplification or AR has enhanced sensitivity to 
pay compensation for low levels of androgen or 
more testosterone is converted to the more potent 
androgen, dihydrotestosterone (DHT) by reductase. 
In the promiscuous pathway, criticalities are 
replaced by generalized patterns. The “specificity 
landscape” of the AR is broadened to encompass 
more non-specific ligands so that it can be activated 
by non-androgenic molecules normally present in 
the circulation. In the outlaw pathway, receptor 
tyrosine kinases (RTKs) are switched on and the AR 
is phosphorylated by either the AKT (protein kinase 
B) or the mitogen-activated protein kinase (MAPK) 
pathway, producing a ligand-independent AR. In the 
bypass pathway, parallel survival pathways, such as 
that involving the anti-apoptotic protein BCL2 (B-
cell lymphoma 2), prevent the need for AR or its 
ligand. Compromising AR expression by siRNA 
induced PI3K-independent activation of Akt, which 
was triggered by calcium/calmodulin-dependent 
kinase II (CaMKII). Expression of CaMKII genes is 
tightly controlled by AR.  
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It dampens CaMKII gene expression whereas 
abolition of AR activity results in an elevated level 
of kinase activity and in enhanced expression of 
CaMKII genes that activate anti-apoptotic PI3K/Akt 
pathways. Refractoriness to apoptosis is faced as 
overexpression of CaMKII genes desensitizes cells 
to apoptosis induced by KN-93, a CaMKII inhibitor, 
or wortmannin, a PI3K/Akt inhibitor, in terms of 
combinatorial drug use with doxorubicin, 
thapsigargin and TRAIL. Moreover, overexpression 
of CaMKII augments secretion of prostate specific 
antigen and promotes cell growth of LNCaP in 
steroid-free condition (illustrated in Fig. 3). There is 
an integration of two distinct transduction pathways 
including AR- and CaMKII-mediated pathways. 
CaMKII is an imperative performer in prostate 
cancer cells ability to escape apoptosis under 
androgen ablation and facilitate the progression of 
prostate cancer cells to an androgen independent 
state (44, 45). KN-93 (CaMKII inhibitor) has a 
broader effect on apoptosis than just inhibition of 
CaMKII: It inhibits AR activity and induces p53-
independent apoptosis, inhibits anti-apoptotic 
protein Mcl-1, upregulates pro-apoptotic protein 
PUMA and generates ROS. Phenotype of prostate 
cancer cells undergoes transition from TRAIL-
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Figure 2: Androgen receptor suppresses the crosstalk of CaMKII with Akt. However if there is an inhibition of AR, it de-represses 
CaMKII. 
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resistant to -sensitive in combinatorial drug 
treatment. This is suggestive of the fact that KN-93 
could be used for novel therapeutic approaches when 
hormonal therapy has failed (46). 
 
Expression Dynamics of Androgen Receptor: 
‘Heads’, It Wins, and ‘Tails’, Therapeutics Lose 
Neoplastic cells have to perpetuate the androgen 
receptor (AR)-mediated dynamics by a wide range 
of integrated pathways that crosstalk at various 
levels. It ensures the robust expression and 
activation of AR-mediated genes. There are 
multidirectional pathways opted for by the AR to 
meet the demands of a desperate cancer-prone 
environment. These pathways have been studied 
elsewhere (47, 48). 
The growth-promoting effects of androgens are 
mediated mostly through the AR. Although PCa is 
heterogeneous in its etiology and progression, 
androgen signaling through the AR seems to be 
involved in all aspects of the disease. The binding of 
the androgen–AR complex to AREs involves 
recruiting coactivators and corepressors to regulate 
transcription of androgen-targeted genes such as 
PSA. Various members of the steroid receptor 
superfamily can recognize the same ARE. However, 
each receptor activates tissue-specific target genes 
under specific physiological conditions. This 
receptor-specific tissue response is due to a complex 
DNA–protein and protein–protein interplay among 
non-receptor coregulatory factors and/or cis-
regulatory sequences. After the binding of native 
ligands, T and DHT, to the AR and in association 
with coregulators, the AR will be phosphorylated 
and translocated to the nucleus, and binds to AREs 
of the AR target gene promoters that induce their 
transcriptional activities. Although androgens are 
important in the maintenance of normal prostate 
homeostasis, complex interactions between peptide 
growth factors and other growth modulators 
regulated either by androgens or by other factors are 
also required. The transcriptional activity of the AR 
is important in prostate development, as well as in 
PCa progression. Androgen binding is the most 
important stimulus to the AR activity; thus, the PCa 
hormonal therapy aims to abolish this stimulus. 
Although hormonal therapy is partly effective, other 
factors can influence downstream AR-mediated 
transcription activity. 
Whether at the level of the AR activation, 
downstream cytoplasmic signaling crosstalk or 
nuclear protein cross-modulation, the net effect in 
patients who have undergone androgen ablation and 
who have relapsed, is the retention of some 
androgen-regulated gene activity. Therefore, it is not 
surprising that much research into signaling and AR 
biology in the prostate is directed at addressing this 
issue. Blockade of peptide growth (trophic) factors 
or their receptors or the blocking of mutated ARs 
that are capable of responding to various stimuli may 
prove effective, and modulation of intermediate 
signaling factors such as MAPKs or coactivators 
may allow the suppression of multiple pathways to 
common DNA targets. G-protein-coupled receptors 
serve as the major receptor family for neuropeptides, 
neurotransmitters and other bioactive peptides (49).  
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G-proteins share a common pathway for a 
multiplicity of neurotransmitter receptor functions 
and have an important role in the regulation of post-
receptor levels including the activation of a variety 
of enzymes, that is, adenylyl cyclase and 
phospholipase C, which then regulate cell function 
through the production of second messengers. These 
second messengers include cyclic AMP (cAMP), 
diacylglycerol and inositol polyphosphates among 
others. Then, these molecules will activate the 
MAPK signaling pathway and several related protein 
kinases such as PKA that lead to the phosphorylation 
of various membrane and cytosolic proteins and to 
the regulation of gene expression by activating a 
variety of transcription factors (50). In addition, 
PKA pathway activation leads to phosphorylation of 
the nuclear transcription factor, cAMP response 
element (CRE)-binding protein (CREB) at Ser 133. 
The CREB binds the CRE of its target genes. It has 
also been shown that CREB-binding protein (CBP) 
enhances AR dependent transcription and this AR 
coactivator integrates androgen-mediated and other 
signaling pathways (51). In addition, in androgen-
sensitive LNCaP cells, a putative ARCRE site forms 
specific and competable protein interactions with 
CREB (52). Li et al. (53) registered a robust 
expression of truncated AR isoforms in 22Rv1 cells 
along with intragenic reconstitution of an 
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approximately 35-kb AR genomic segment 
harboring a cluster of alternative AR exons. Cloning 
of the break fusion junction in 22Rv1 cells displayed 
long interspersed nuclear elements (LINE-1) 
encompassing the rearranged segment and a 
microhomology-mediated break-induced replication. 
Henceforth, intragenic rearrangements have emerged 
as new mediators in cancer progression. Some other 
variants documented by other research groups are 
mentioned in figure 1 (12, 41, 54, 55). Arachidonic 
acid pathway members PLA2G7, HPGD, EPHX2 
and CYP4F8 were identified as putative novel 
therapeutic targets in prostate cancer. EPHX2 and 
PLA2G7 correlated with AR and their inhibition 
reduced AR signaling. It is obvious that inhibition of 
these enzymes may be effective when combined 
with other treatments, such as androgen deprivation 
(56). Lately, Kim et al. (57) have found that 
HOXB13 is a protein that is involved in suppression 
of AR-mediated signal transduction. This protein is 
downregulated in prostate carcinogenesis. Future 
research might converge upon mechanisms of 
restoration of the negative regulators of AR 
signaling. There are some other proteins which 
coexist at the promoter region and are involved in 
activation of target genes. H2A.Z and ubiquitin-
specific protease 10 are each required for 
transcriptional activation of the AR regulated 
prostate-specific antigen and KLK3 genes (58). 
A combinatorial drug design seems to dampen the 
key regulators which augment disease progression. 
Pharmacological targeting of STAT5 retards 
carcinogenesis because STAT5 cooperates with AR 
and favors cancer progression and aggressiveness 
(59). Yang et al. (60) stated that HDAC4 enhances 
AR SUMOylation, raising the likelihood that 
deacetylase may act as an E3 ligase for AR 
SUMOylation. Knockdown of HDAC4 increases the 
activity of endogenous AR. Further studies are 
important to explore antineoplastic detailed 
mechanistic insights. Another tumor suppressor 
gene, BTG2, is downregulated in prostate cancer, 
and the re-establishment of this gene in BTG2-
deficient cells has been shown to inhibit prostate 
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cancer cell growth (61). On a similar note, GLI1, 
important for Sonic hedgehog signal transduction, 
can act as a corepressor to considerably inhibit AR-
mediated transactivation (62). Tan et al. (63) stated 
that treatment of AR by dihydrotestosterone potently 
activated GRP78 expression, and there was a 
coexistence of GRP78 with Hsp70-Hsp90 client 
proteins. All these proteins limit the efficacy of 
drugs. A multipronged drug design is necessary to 
checkmate this group of negative regulators. 
Accumulating data mark these AR variants as 
candidates for therapies directly targeting the AR 
rather than the ligand. Castration-resistant prostate 
cancer cells express variant ARs which included 
truncated ARs lacking the carboxyterminal ligand-
binding domain, and small interfering RNA-
mediated knockdown efficiently suppressed 
androgen-independent cell growth. Nigericin like 
compounds suppress AR expression at the 
messenger RNA level. These could be applied as 
new-type therapeutic agents that inhibit a broad 
spectrum of AR variants in hormone-refractory 
prostate cancer (45). However, there are some 
compensatory pathways which are switched on 
impairment of AR. Ablation of AR in in vitro cells 
induced PI3K-independent activation of Akt, which 
was triggered by calcium/calmodulin-dependent 
kinase II (CaMKII) (43, 64). It has lately been found 
that grape seed extract potently inhibits histone 
acetyl transferase, leading to decreased AR-mediated 
transcription and cancer cell growth (65). Similarly, 
procyanidin B3, an inhibitor of histone 
acetyltransferase, has broader implications in the 
inhibition of p300-dependent acetylation of ARs 
(66). After having outlined the current approaches 
for treating prostate cancer, we now focus on 
emerging therapeutic opportunities for prostate 
cancer aggressiveness that are based on recent 
insights into molecular off-track activities of AR. 
Targeted therapeutics, particularly those that restrain 
the activity of ARs that are mutated and/or 
overexpressed in cancer, have revolutionized the 
treatment. Hsp90-based therapy has so far shown 
inadequate activity in the clinic. In accordance with 
the same interpretation, efficacy of a novel 
mitochondrial-targeted, small-molecule Hsp90 
inhibitor, gamitrinib (GA mitochondrial matrix 
inhibitor), was evaluated by Kang et al. (67) in the 
Transgenic Adenocarcinoma of the Mouse Prostate 
model.  
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of localized and metastatic prostate cancer in 
immunocompetent mice. Another drug that has 
wider implications in blocking cancer activity is 
MDV3100; it blocks ligand receptor engagement 
and prevents nuclear shuttling of AR and coactivator 
recruitment of the ligand- receptor architecture (68) . 
 
Targeting Chromatin-Modifying AR Co-
Activators or AR Stability 
Growing evidence has shown that co-regulators 
(factors recruited by transcription factors to either 
activate or repress transcription) are indispensable 
components of transcriptional regulation. AR, as a 
nuclear receptor, is no exception. AR co-regulators, 
such as FHL2 (four and a half LIM domains 2), have 
been reported previously (69). However recently, 
several chromatin modifying enzymes, namely 
histone demethylase proteins, were shown to 
complex with AR and facilitate its activation of gene 
targets (70). 
 
Histone demethylases  
Histone methylation was original thought to be a 
stable, irreversible mark as only histone methyl-
transferases had been identified. However, the 
discovery of the first histone demethylase LSD1 
(Lysine-specific demethylase 1), also known as 
AOF2 (Amine amine oxidase (flavin containing) 
domain 2) or KDM1 (Lysine (K) demethylase 1) in 
2004 proved that histone methylation is reversible 
(71). Since then, a dozen more histone demethylases 
have been identified. Histone lysine methylation is a 
dynamic and versatile process, which has been 
observed on a number of lysine residues on histone 
proteins (72). The balance between repressive and 
active histone modifications (also known as the 
histone code) ultimately determines whether a gene 
will be actively transcribed or repressed, and AR 
target genes are no exception. The status of histone 
lysine methylation has been shown to be important 
for AR signaling, and several histone demethylase 
proteins are expressed or upregulated in prostate 
cancer. These include LSD1 and the Jumonji class of 
proteins, which include JMJD2C (Jumonji domain 
containing 2C, also known as GASC1 (Gene 
amplified in squamous cell carcinoma 1) and 
KDM4C (Lysine (K) demethylase 4C)), JMJD1A 
(Jumonji domain containing 1A, also known as 
JHDM2A (Jumonji domain containing histone 
demethylase 2A), and KDM3A (Lysine (K) 
demethylase 3A)), and JARID1B (Jumonji, AT rich 
interactive domain 1B, also known as PLU-1 and 
KDM5B (Lysine (K) demethylase 5B) (73). While 
the transcriptional targets of these proteins are 
largely unknown, all 4 complex with AR and 
facilitate its activation of downstream signaling 
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pathways. Although the recruitment of JMJD1A to 
target genes was shown to occur solely in the 
presence of androgens, LSD1 and JMJD2C are 
bound to AR target genes even in the absence of 
androgen ligand or AR binding (74). 
Interference with these histone demethylases with 
siRNA or pharmacological inhibitors leads to 
distinct changes in histone marks at AR target 
promoters. LSD1 is the best studied histone 
demethylase, and its activity and target specificity 
are largely dependent on interacting factors. In fact, 
it is a component of several transcriptional 
complexes (75). While LSD1 may demethylate the 
active di-methyl lysine 4 (2MK4) mark on histone 
H3, which leads to reduced gene expression, at AR 
target genes, several reports show that LSD1 binds 
to AR target AREs and facilitates demethylation of 
the repressive mono (1MK9) and di-methyl lysine 9 
(2MK9) marks on histone H3 upon recruitment of 
ligand-bound AR, which results in transcriptional de
-repression (76, 77). The demethylase activity of 
LSD1 is essential for this process, as deletion of the 
enzymatic domain of LSD1 or siRNA to LSD1 
reduces androgen-induced transcriptional activation 
of AR targets, although direct biochemical evidence 
for LSD1 demethylation of 1MK9 and 2MK9 in cell 
-free systems is lacking. LSD1 may also mediate 
prostate cancer aggressiveness as high LSD1 mRNA 
levels or reduced levels of the 2MK4 mark on 
histone H3 that LSD1 demethylates, are significantly 
associated with prostate cancer recurrence, making 
these promising prognostic markers (78). Likewise, 
JMJD1A interference leads to increased levels of the 
repressive 2MK9 mark at AR target genes, which 
attenuates AR target gene transcriptional activation 
by ligand-bound AR. Unlike LSD1, 1MK9 and 
2MK9 have been shown, in cell-free assays, to be 
direct substrates of JMJD1A. Like LSD1, however, 
knockdown of JMJD1A does not block AR 
recruitment, suggesting these two demethylases 
function after AR binding to facilitate AR’s 
transcriptional program. Unlike LSD1 though, 
promoter occupancy of JMJD1A is dependent upon 
the presence of androgens or AR binding to its target 
genes, and RNA interference of JMJD1A results in 
more pronounced effects on blocking activation of 
AR targets than RNA interference of LSD1. Finally, 
JMJD1A expression is increased in response to 
androgens, although it is not clear whether JMJD1A 
is an AR target gene (79). The expression of another 
Jumonji class protein, JMJD2C, is also induced by 
androgens.  
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JMJD2C may catalyze the removal of the repressive 
di and tri-methyl lysine 9 mark on histone H3(80). 
More importantly, JMJD2C interacts with LSD1 and 
co-localizes with LSD1 and AR at AR target gene 
AREs. Together, these two demethylases lead to the 
removal of repressive tri-, di-, and mono-methyl 
marks from lysine 9 on histone H3 to activate 
transcription of AR target genes. In addition, it was 
recently shown that JARID1B, whose only known 
substrate is the active methylated-H3K4 marks, 
interacts with AR. In reporter assays, JARID1B 
enhanced transcriptional activation by AR while a 
JARID1B mutant that was unable to bind AR did 
not. Finally, JARID1B is upregulated in prostate 
cancers samples compared to benign prostate 
samples. It can be concluded that, considering the 
importance of these enzymes in the activation of AR 
target genes, inhibition of these enzymes may be a 
rational, non-hormonal strategy to disrupt AR 
signaling. Efficient inhibitors of JmjC domain-
containing histone demethylases have yet to be 
discovered, but two classes of LSD1 inhibitors have 
been identified. The first class is MAOIs 
(monoamine oxidase inhibitors) such as pargyline, 
which have been used clinically as antidepressants 
and which may also inhibit LSD1 activity. In 
addition, polyamine analogues, which have been 
previously shown to inhibit cancer cell growth and 
more recently which have been shown to inhibit 
LSD1 from demethylating the active 2MK4 mark, 
represent another class of agents to target LSD1, 
although the effect on AR target genes remains 
poorly characterized (81).  
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Conclusion 
Spreading cancer before and after surgical, chemical or radiological treatment is one of the biggest challenge 
in the management of a cancer patient.  Diagnosis of cancer metastasis could be a valuable approach while 
treating the cancer as prognostic factors helped in the survival of patients and reduce mortality rate. Prostate 
cancer, a major type of cancer in male, can be diagnosed by several molecular factors like PSA expression but 
diagnosis its metastatic stage is a challenging task. In this review, we have focused on the utilization of 
androgen receptors as a significant tool to diagnosis PCa metastasis state. 
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